Protocol No.: OCR16451
Sponsor Protocol No.: INTREPID-FEVER; BMD-1111
Protocol Title.: Impact of Fever Prevention in Brain Injured Patients
Principal Investigator: Busl, Katharina
Objective: This study will assess the impact of fever prevention on fever burden and short- and long-term neurologic outcomes in brain injured patients. Half of the subjects will undergo fever prevention using a targeted temperature management system and half of the subjects will be treated for fever should it develop.
Description: Multiple studies demonstrate that fever / elevated temperature is associated with poor outcomes in brain injured patients; however, there are no conclusive studies that demonstrate that fever prevention/controlled normothermia is associated with better outcomes. This study will be conducted to assess the impact of advanced temperature control to prevent fever in brain injured patients. The fever prevention group will use the Arctic Sun Temperature Management System and will be compared to standard care patients in whom fever may spontaneously develop. If fever develops in a patient in the standard care group, they will be treated with standard fever care measures according to a step-wise algorithm, consisting primarily of intermittent antipyretics (e.g., acetaminophen) and cooling blankets and, when necessary, advanced targeted temperature management devices.
Age Group: Adult
Age: 21 Years - 85 Years
Experimental: Fever PreventionFever will be prevented using a surface targeted temperature management system
Active Comparator: Standard CareStandard care in which fever may spontaneously develop
Detailed Eligibility: Inclusion Criteria: 1. Admitted with a primary neurological diagnosis of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage 2. Prior to onset of acute symptoms, was considered functionally independent (mRS 0-2) 3. Meets disease-specific criteria Exclusion Criteria: 1. Fever (≥38°C) prior to study enrollment 2. Pre-existing neurological, psychiatric, or other condition that would confound neurological assessment or would make it difficult to accurately assess neurologic and/or functional outcome 3. Has a pre-morbid condition with poor likelihood of survival to 6 months 4. Has a pre-morbid mRS ≥3 5. Diagnosed with brain death 6. Is undergoing therapeutic hypothermia therapy 7. Has sustained neurological injury felt to be catastrophic with little chance of recovery 8. Has a skin condition in which the use of the ArcticGel Pads is contraindicated (i.e., skin that has signs of ulceration, burns, hives, or rash) 9. Has poor skin integrity or poor tissue perfusion 10. Participation in a concurrent investigational / interventional study (medical device or drug)